Developing novel biologics for autoimmune diseases
Jade’s focus is to develop transformational, disease-modifying therapies targeting autoimmune diseases. The company’s lead candidate, JADE101, is a potentially best-in-class monoclonal antibody designed to inhibit the cytokine APRIL (A PRoliferation Inducing Ligand). A Phase 1 clinical trial evaluating JADE101 in healthy volunteers is ongoing, with interim, biomarker-rich data expected in the first half of 2026. Jade’s pipeline also includes JADE201, an anti-BAFF-R (B-cell activating factor receptor), and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development.
|
Program
|
Candidate
|
Discovery
|
IND-Enabling
|
Phase 1
|
Expected Milestones
|
Potential Indications
|
|
|---|---|---|---|---|---|---|---|
| MOA: Anti-aprilJADE-001
| JADE101
|
| Interim Data:
1H 2026 | IgAN
|
|||
|
JADE101 is a potential best-in-class monoclonal antibody designed to block the APRIL (A PRoliferation Inducing Ligand) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE101 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function. Learn more Learn more |
|||||||
| MOA: ANTI-BAFF-RJADE-002
| JADE201
|
| Planned FIH:
1H 2026 | Multiple systemic AI diseases
|
|||
|
JADE201 is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R (B-cell activating factor receptor), a clinically validated pathway in autoimmune disease. It is designed with a dual mechanism of action: blocking BAFF signaling to inhibit B cell survival and enhancing effector functions to directly eliminate B cells. |
|||||||
| MOA: UndisclosedJADE-003
|
| Planned FIH:
1H 2027 | Undisclosed
|
||||
|
|
|||||||
JADE101 is a potential best-in-class monoclonal antibody designed to block the APRIL (A PRoliferation Inducing Ligand) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE101 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.
Learn more Learn moreJADE201 is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R (B-cell activating factor receptor), a clinically validated pathway in autoimmune disease. It is designed with a dual mechanism of action: blocking BAFF signaling to inhibit B cell survival and enhancing effector functions to directly eliminate B cells.